M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Seres Therapeutics is promoting its chief operating and financial officer, Eric Shaff, to succeed Roger Pomerantz as its new president and CEO.
Buoyed by the improved outlook, the agency has predicted its core drug evaluation activities will be unaffected by the Brexit-enforced move.
Aimmune has confirmed that the government shutdown will delay the FDA’s review of AR101, its oral immunotherapy for peanut allergy.
Roche's Omar Khwaja, M.D., Ph.D., will become chief medical officer at gene therapy specialist Voyager Therapeutics.
Paul Streck, M.D., will this week exit his role as chief medical officer of Insmed to “pursue an employment opportunity on the West Coast.”
Berman spent the past decade overseeing the rise of immuno-oncology drugs at AstraZeneca and Bristol-Myers Squibb.
In mouse models, a combo of diabetes treatment Avandia and cancer drug Mekinist turns some breast tumor cells into fat.
Bloomberg reports that Sean Bohen, CMO and EVP of global medicines development, is out the door at AstraZeneca.
Aslan has been hit by the news that its lead drug varlitinib missed the mark in a gastric cancer trial, sending its shares down almost 16%.
The dual PDE3/PDE4 inhibitor failed to beat placebo on a measure of lung function, wiping more than 30% off Verona’s share price.
